Theodosia Teo

Theodosia Teo

Auto-generated profile, based on publicly available information

Theodosia Teo

Drug Discovery and Development, Cancer Research Institute, Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, 5000, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SPStephen Philip
Stephen Philip
MKMalika Kumarasiri
Malika Kumarasiri
TTTheodosia Teo
Theodosia Teo
MYMingfeng Yu
Mingfeng Yu
SWShudong Wang
Shudong Wang

1 April 2014 in Chemistry & Biology
Verified
Journal Article
Closed access
SDSarah Diab
Sarah Diab
MKMalika Kumarasiri
Malika Kumarasiri
MYMingfeng Yu
Mingfeng Yu
TTTheodosia Teo
Theodosia Teo
CPChristopher Proud
Christopher Proud
SWShudong Wang
Shudong Wang

12 February 2014 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
SDSarah Diab
Sarah Diab
TTTheodosia Teo
Theodosia Teo
MKMalika Kumarasiri
Malika Kumarasiri
PLPeng Li
Peng Li
MYMingfeng Yu
Mingfeng Yu
SWShudong Wang
Shudong Wang

16 February 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
STSolomon Tadesse
Solomon Tadesse
MYMingfeng Yu
Mingfeng Yu
Laychiluh Bantie MekonnenLaychiluh Bantie Mekonnen
Laychiluh Bantie Mekonnen
FLFrankie Lam
Frankie Lam
SISaiful Islam
Saiful Islam
SWShudong Wang
Shudong Wang
Cyclin D dependent kinases (CDK4 and CDK6) regulate entry into S phase of the cell cycle and are validated targets for anticancer drug discovery. Herein we detail the discovery of a novel series of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as highly potent and selective inhibitors of CDK4 and CDK6. Medicinal chemistry optimization resulted in 83, an orally bioavailable inhibitor molecule with remarkable selectivity. Repeated oral administration of 83 caused marked inhibition of tumor growth in MV4-11 acute myeloid leukemia mouse xenografts without having a negative effect on body weight and showing any sign of clinical toxicity. The data merit 83 as a clinical development candidate.

9 August 2019 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
Muhammed RahamanMuhammed Rahaman
Muhammed Rahaman
FLFrankie Lam
Frankie Lam
LZLongjin Zhong
Longjin Zhong
TTTheodosia Teo
Theodosia Teo
JAJulian Adams
Julian Adams
SWShudong Wang
Shudong Wang
Colorectal cancer (CRC) remains one of the most lethal human malignancies, and pursuit of new therapeutic targets for treatment has been a major research focus. Cyclin‐dependent kinase 9 (CDK9), which plays a crucial role in transcription, has emerged as a target for cancer treatment. CDKI‐73, one of the most potent and pharmacologically superior CDK9 inhibitors, has demonstrated excellent anti‐tumour efficacy against several types of cancers. In this study, we evaluated its therapeutic potential against CRC. CDKI‐73 elicited high cytotoxicity against all colon cancer cell lines tested. Cell cycle and apoptosis analysis in HCT 116 and HT29 cells revealed that CDKI‐73 induced cell death without accumulation of DNA at any phase of the cell cycle. Moreover, it caused depolarisation of mitochondrial membrane, leading to caspase‐independent apoptosis. Knockdown by shRNA demonstrated the CDK9‐targeted mechanism of CDKI‐73, which also affected the Mnk/eIF4E signalling axis. In addition, RT‐qPCR analysis showed that CDKI‐73 down‐regulated multiple pro‐survival factors at the mRNA level. Its in vivo anti‐tumour efficacy was further evaluated in Balb/c nude mice bearing HCT 116 xenograft tumours. CDKI‐73 significantly inhibited tumour growth (***P < 0.001) without overt toxicity. Analysis of the tumour tissues collected from the xenografted animals confirmed that the in vivo anti‐tumour efficacy was associated with CDK9 targeting of CDKI‐73. Overall, this study provides compelling evidence that CDKI‐73 is a promising drug candidate for treating colorectal cancer.

10 March 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TLTiangong Lu
Tiangong Lu
AGAik Wye Goh
Aik Wye Goh
MYMingfeng Yu
Mingfeng Yu
JAJulian Adams
Julian Adams
FLFrankie Lam
Frankie Lam
SWShudong Wang
Shudong Wang